# A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

> **NCT05910827** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hummingbird Bioscience** · enrollment: 398 (estimated)

## Conditions studied

- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Advanced Cutaneous Squamous Cell Carcinoma
- Nasopharyngeal Cancinoma (NPC)
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** HMBD-001
- **DRUG:** Docetaxel
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05910827
- **Lead sponsor:** Hummingbird Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910827, "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05910827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*